

June 20, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), as amended, we hereby inform you that Mr. Rajesh Desai (DIN: 00007960) will cease to be an Independent Director of the Company with effect from end of 25th June, 2025, consequent to the completion of his term of office as an Independent Director.

Consequent to the aforesaid cessation, the following committees of the Board have been reconstituted as under:

Sr. No.	Committees of the Board	Composition of the Committees with effect from 26th June, 2025
1.	Audit Committee	Mrs. Vijayalakshmi Iyer – Chairperson Ms. Saira Ramasastry – Member Mr. Dipankar Bhattacharjee – Member
2.	Stakeholders Relationship Committee	Ms. Saira Ramasastry – Chairperson Mrs. Cherylann Pinto - Member Mr. Anurag Mantri - Member
3.	Risk Management Committee	Mr. Dipankar Bhattacharjee – Chairman Mr. Glenn Saldanha – Member Mr. Anurag Mantri – Member

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are provided in Annexure-A.

You are requested to take the same on record.

Thanking You.

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

ANNEXURE – A

Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Completion of term of office of Mr. Rajesh Desai as an Independent Director of the Company.
Date of Cessation	Mr. Rajesh Desai will cease to be an Independent Director with effect from the end of 25th June, 2025
Brief Profile (in case of appointment)	Not Applicable
Disclosure of Relationships between Directors (in case of appointment of a director)	Not Applicable

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com